Samsung Biologics, South Korea-based contract development and manufacturing organization (CDMO), has announced that its Plant 4, the world's largest single bio manufacturing plant, has commenced GMP operations this month.

Plant 4's partial operations comes just 23 months after construction began in November 2020, adding fresh production capacity of 60,000 liters. Plant 4 will have a total capacity of 240,000 liters when it becomes fully completed in the first half of next year.

Plant 4 is expected to help Samsung Biologics maximize operational efficiency in addition to further enhancing its scale up development and manufacturing capability in response to growing biopharmaceutical demand.

Upon the full completion of Plant 4, Samsung Biologics will boast a total capacity of 604,000 liters at Bio Campus I, the world's largest bio manufacturing site, and account for nearly 30% of the global CDMO manufacturing capacity. Samsung Biologics has already sealed a number of large-scale manufacturing contracts with presales activities for Plant 4.

The company has also acquired additional land for Bio Campus II, which will host Plants 5 through 8, as well as an Open Innovation Center. Construction is set to begin later this year and will be 30% larger in size compared to Bio Campus I.